Genexine succeeds in transferring ‘Interleukin 7’ technology worth of total USD 560 million
Genexine succeeded in transferring technology worth of total USD 560 million.
Genexine publicly announced the company signed a technology transfer agreement of ‘Interleukin 7(long-acting IL-7 cytokine designated as GX-17)’ with Chinese I-Mab Biopharma.
The agreement terms and conditions inclu...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
